Bioventus Overview
Valuation check: BVS's ROE is 23.86%, above the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow23.86%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bioventus (BVS) currently reports a ROE of 23.86%. That is above the Healthcare sector average of 21.28%. Use the charts on this page to explore Bioventus's ROE history and peer comparisons.
Bioventus's ROE of 23.86% is higher than the Healthcare sector average of 21.28%. That is roughly 12.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bioventus's current 23.86% should be judged against Healthcare norms (sector average: 21.28%) and against BVS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 23.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Bioventus, and consider following BVS for alerts when major investors trade the stock.
Bioventus is classified in the Healthcare sector. On ROE, it currently shows 23.86% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BVS with unrelated industries.
